TKPHF (TKPHF) Stock Price & Analysis
TKPHF (TKPHF) fell 9.59% to USD 31.19 as of July 25, 2026 at 03:05 UTC, according to Nexqual real-time market data.
TKPHF last closed at USD 34.5; the session ranged USD 32.6–32.6 on volume of 200 shares. Market capitalization is $49.80B, with a 52-week range of USD 26.33–39.2 (PNK). Source: Nexqual, July 25, 2026 at 03:05 UTC.
Key Statistics (as of July 25, 2026 at 03:05 UTC)
| Price | USD 31.19 |
|---|---|
| Change | ▼ 9.59% (down) |
| Previous Close | USD 34.5 |
| Open | USD 32.6 |
| Day Range | USD 32.6 – 32.6 |
| 52-Week Range | USD 26.33 – 39.2 |
| Volume | 200 shares |
| Market Cap | $49.80B |
| Exchange | PNK |
Technical Analysis (TKPHF)
Nexqual's technical model rates TKPHF "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of July 25, 2026 at 03:05 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.49 (neutral) |
| vs SMA50 | Below (USD 32.19) |
| MACD | 0.56 (positive) |
Analyst Ratings (TKPHF)
Wall Street analysts rate TKPHF "None", per Nexqual as of July 25, 2026 at 03:05 UTC.
| Consensus Rating | None |
|---|
Earnings (TKPHF)
| Next Earnings Date | 2026-07-30 |
|---|---|
| Revenue Estimate | $1.15T |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financials & Fundamentals (TKPHF)
| Total Revenue | $4.51T |
|---|---|
| Revenue Growth (YoY) | +3.90% |
| Gross Margin | +64.06% |
| Operating Margin | +11.11% |
| Profit Margin | -3.38% |
| ROE | -2.12% |
| Debt / Equity | 73.7 |
| Current Ratio | 1.09 |
| Total Cash | $595.05B |
| Total Debt | $5.48T |
| Free Cash Flow | $672.78B |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Financial Health Score (TKPHF)
Nexqual rates TKPHF's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 03:05 UTC.
| Growth | Strong — Revenue +676% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 64%, operating 11% |
| Balance Sheet | Solid — $595.1B cash vs $5.48T debt |
| Cash Flow | Solid — FCF $672.8B, 15% margin |
| Efficiency | Critical — ROE -2%, ROA 2.6% |
Ownership (TKPHF)
| Insider Ownership | +0.03% |
|---|---|
| Institutional Ownership | +50.45% |
| Shares Outstanding | 1.60B |
| Float | 1.58B |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Leadership (TKPHF)
TKPHF is led by So-Young Kim (age 55), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:05 UTC.
| CEO, President & Director | So-Young Kim (age 55) |
|---|---|
| CFO & Director | Milano Furuta (age 47) |
| President of Research & Development and Representative Director | Andrew S. Plump (age 60) |
| Chief Operating Officer | Michael Fox |
| Senior Vice President of Corporate Finance & Controlling Department | Iwaaki Taniguchi |
Major Backers & Investors (TKPHF)
Notable institutional backers of TKPHF include Capital Group, Goldman Sachs, Fidelity, according to Nexqual as of July 25, 2026 at 03:05 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 0.83% |
| Goldman Sachs | 0.64% |
| Fidelity | 0.37% |
| Capital Income Builder | 0.37% |
| Investment Co of America | 0.33% |
| Pacer Advisors, Inc. | 0.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.39% |
| BlackRock | 1.49% |
Source: Nexqual, July 25, 2026 at 03:05 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DSKYF | Daiichi Sankyo Co., Ltd. | USD 17.52 | ▲ 2.88% |
| CHGCY | Chugai Pharmaceutical Co., Ltd. | USD 22 | ▼ 1.57% |
| ALPMF | Astellas Pharma, Inc. | USD 12.85 | ▲ 0% |
| MKKGY | Merck KGaA | USD 31.88 | ▲ 2.02% |
| BAYZF | Bayer A.G. | USD 52.8 | ▼ 3.93% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:05 UTC. This page is informational and not investment advice.